The Patent Finder

Loxo Oncology, Inc.

27 patents currently held · Updated Nov 21, 2026
13 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jun 2035
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 9, 2027
    The maintenance fee for Compounds Useful as Kinase Inhibitors (US 10,342,780) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
  • 1 fee due Mar 3, 2027
    The maintenance fee for Pyrazolopyrimidine Derivatives as BTK Inhibitors for the Treatment of Cancer (US 10,399,989) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
  • 3 fees due May 5 to 28, 2027 · next May 5
  • 1 fee due Jul 21, 2027
    The maintenance fee for Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase (US 10,538,524) comes due Jul 21, 2027. Unpaid by Jan 21, 2028, it lapses early.
  • 1 fee due Sep 17, 2027
    The maintenance fee for Methods of Treating Pediatric Cancers (US 10,588,908) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
  • 2 fees due Oct 7 to 23, 2027 · next Oct 7

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,975,897Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase
In force
 · USPTO record
In forceUSPTO record
US 10,538,524Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase
In force
 · USPTO record
In forceUSPTO record
US 10,399,989Pyrazolopyrimidine Derivatives as BTK Inhibitors for the Treatment of Cancer
In force
 · High confidence
In forceHigh confidence
US 10,611,766Pyrazolopyrimidine Derivatives as BTK Inhibitors for the Treatment of Cancer
In force
 · High confidence
In forceHigh confidence
US 10,342,780Compounds Useful as Kinase Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 10,464,905Compounds Useful as Kinase Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 10,695,323Compounds Useful as Kinase Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 10,918,622Compounds Useful as Kinase Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 11,826,351Compounds Useful as Kinase Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 12,220,401Compounds Useful as Kinase Inhibitors
In force
 · Medium confidence
In forceMedium confidence
10 of 27 patents shown.
Pro members see all 27.
Pro members: see all 27 patents
Also on record, not counted in the 27: 13 patents in force now held by others · 6 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 pending · 3 abandoned · 3 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited